Kenvue (KVUE) Expected to Announce Earnings on Thursday

Kenvue (NYSE:KVUE) is expected to release its earnings data before the market opens on Thursday, February 6th. Analysts expect Kenvue to post earnings of $0.26 per share and revenue of $3.79 billion for the quarter. Kenvue has set its FY 2024 guidance at 1.100-1.200 EPS and its FY24 guidance at $1.10-1.20 EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s revenue was down .4% on a year-over-year basis. During the same period last year, the firm posted $0.31 EPS. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Trading Down 0.3 %

NYSE:KVUE opened at $21.22 on Tuesday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue has a 52-week low of $17.67 and a 52-week high of $24.46. The stock’s 50 day moving average price is $21.90 and its 200 day moving average price is $21.92. The company has a market capitalization of $40.69 billion, a PE ratio of 38.59, a P/E/G ratio of 2.05 and a beta of 1.45.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.86%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Barclays dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a report on Monday. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Bank of America raised their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Finally, Citigroup cut their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.